Publikationen

Feldkamp, J., Führer, D., Luster, M., Musholt, T. J., Spitzweg, C., & Schott, M. (2016). Fine Needle Aspiration in the Investigation of Thyroid Nodules. Deutsches Arzteblatt International, 113(20), 353–359. http://doi.org/10.3238/arztebl.2016.0353


French, J. D., Bible, K., Spitzweg, C., Haugen, B. R., & Ryder, M. (2016). Leveraging the immune system to treat advanced thyroid cancers. The Lancet. Diabetes & Endocrinology. http://doi.org/10.1016/S2213-8587(16)30277-7


Hagenhoff, A., Bruns, C. J., Zhao, Y., Lüttichau, von, I., Niess, H., Spitzweg, C., & Nelson, P. J. (2016). Harnessing mesenchymal stem cell homing as an anticancer therapy. Expert Opinion on Biological Therapy, 16(9), 1079–1092. http://doi.org/10.1080/14712598.2016.1196179


Kazmierczak, P. M., Rominger, A., Wenter, V., Spitzweg, C., Auernhammer, C., Angele, M. K., et al. (2017). The added value of (68)Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin. European Radiology, 27(4), 1676–1684. http://doi.org/10.1007/s00330-016-4475-3


Lehner, S., Lang, C., Kaissis, G., Todica, A., Zacherl, M. J., Boening, G., et al. (2015). (124)I-PET Assessment of Human Sodium Iodide Symporter Reporter Gene Activity for Highly Sensitive In Vivo Monitoring of Teratoma Formation in Mice. Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging, 17(6), 874–883. http://doi.org/10.1007/s11307-015-0857-1


Müller, A. M., Schmohl, K. A., Knoop, K., Schug, C., Urnauer, S., Hagenhoff, A., et al. (2016). Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery. Oncotarget, 7(34), 54795–54810. http://doi.org/10.18632/oncotarget.10758


Riester, A., Weismann, D., Quinkler, M., Lichtenauer, U. D., Sommerey, S., Halbritter, R., et al. (2015). Life-threatening events in patients with pheochromocytoma. European Journal of Endocrinology, 173(6), 757–764. http://doi.org/10.1530/EJE-15-0483


Schmohl, K. A., Gupta, A., Grünwald, G. K., Trajkovic-Arsic, M., Klutz, K., Braren, R., et al. (2017). Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. Oncotarget. http://doi.org/10.18632/oncotarget.16499


Schmohl, K. A., Müller, A. M., Wechselberger, A., Rühland, S., Salb, N., Schwenk, N., et al. (2015). Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin αvβ3. Endocrine-Related Cancer, 22(6), 941–952. http://doi.org/10.1530/ERC-15-0245
Spitzweg, C., Morris, J. C., & Bible, K. C. (2016). New drugs for medullary thyroid cancer: new promises? Endocrine-Related Cancer, 23(6), R287–97. http://doi.org/10.1530/ERC-16-0104


Urnauer, S., Klutz, K., Grünwald, G. K., Morys, S., Schwenk, N., Zach, C., et al. (2017). Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes. The Journal of Gene Medicine. http://doi.org/10.1002/jgm.2957


Urnauer, S., Morys, S., Krhac Levacic, A., Müller, A. M., Schug, C., Schmohl, K. A., et al. (2016). Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene. Molecular Therapy : the Journal of the American Society of Gene Therapy, 24(8), 1395–1404. http://doi.org/10.1038/mt.2016.95


Vattai, A., Akyol, E., Kuhn, C., Hofmann, S., Heidegger, H., Koch, von, F., et al. (2017). Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer. Journal of Cancer Research and Clinical Oncology. http://doi.org/10.1007/s00432-017-2420-8


Wendler, J., Kroiss, M., Gast, K., Kreissl, M. C., Allelein, S., Lichtenauer, U., et al. (2016). Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. European Journal of Endocrinology, 175(6), 521–529. http://doi.org/10.1530/EJE-16-0574

Schmohl KA, Müller AM, Schwenk N, Knoop K, Rijntjes E, Köhrle J, Heuer H, Bartenstein P, Göke B, Nelson PJ, Spitzweg C. Establishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice.
Eur Thyroid J. 2015 Sep;4(Suppl 1):74-80. doi: 10.1159/000381019. Epub 2015 May 23.
PMID: 26601076

Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, Halbritter R, Penning R, Spitzweg C, Schopohl J, Beuschlein F, Reincke M. Life-threatening events in patients with pheochromocytoma.
Eur J Endocrinol. 2015 Dec;173(6):757-64. doi: 10.1530/EJE-15-0483. Epub 2015 Sep 7.
PMID: 26346138

Schmohl KA, Müller AM, Wechselberger A, Rühland S, Salb N, Schwenk N, Heuer H, Carlsen J, Göke B, Nelson PJ, Spitzweg C.Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin αvβ3.
Endocr Relat Cancer. 2015 Dec;22(6):941-52. doi: 10.1530/ERC-15-0245. Epub 2015 Aug 25.
PMID: 26307023

Knoop, K., Schwenk, N., Schmohl, K., Müller, A., Zach, C., Cyran, C., et al. (2015). Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 56(4), 600–606. http://doi.org/10.2967/jnumed.114.146662


Lehner, S., Lang, C., Kaissis, G., Todica, A., Zacherl, M. J., Boening, G., et al. (2015). (124)I-PET Assessment of Human Sodium Iodide Symporter Reporter Gene Activity for Highly Sensitive In Vivo Monitoring of Teratoma Formation in Mice. Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging. http://doi.org/10.1007/s11307-015-0857-1


Rühland, S., Wechselberger, A., Spitzweg, C., Huss, R., Nelson, P. J., & Harz, H. (2015). Quantification of in vitro mesenchymal stem cell invasion into tumor spheroids using selective plane illumination microscopy. Journal of Biomedical Optics, 20(4), 040501. http://doi.org/10.1117/1.JBO.20.4.040501


Spitzweg, C., Auernhammer, C. J., Geisler, J., Böck, S., Heinemann, V., Bartenstein, P., & Göke, B. (2015). [Advanced radioiodine-refractory differentiated thyroid cancer]. Deutsche Medizinische Wochenschrift (1946), 140(3), 168–171. http://doi.org/10.1055/s-0041-100196

Führer D, Mann K, Feldkamp J, Krude H, Spitzweg C, Kratzsch J & Schott M 2014 [Thyroid dysfunction in pregnancy]. Deutsche Medizinische Wochenschrift (1946) 139 2148–2152. (doi:10.1055/s-0034-1387300)

Kreissl MC, Jacob C, Führer D, Karges W, Luster M, Lux MP, Mann K, Mittendorf T, Schott M, Spitzweg C et al. 2014 Best supportive care from the conservative/non-surgical perspective and its costs in the treatment of patients with advanced medullary thyroid cancer: results of a Delphi panel. Oncology Research and Treatment 37 316–322. (doi:10.1159/000362613)

Spitzweg C, Bible KC, Hofbauer LC & Morris JC 2014 Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. The Lancet. Diabetes & Endocrinology 2 830–842. (doi:10.1016/S2213-8587(14)70051-8)

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B et al. 2013 Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 54 1450–1457. (doi:10.2967/jnumed.112.115493)

Grünwald GK, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Göke B, Holm PS & Spitzweg C 2013 Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus. Gene Therapy 20 625–633. (doi:10.1038/gt.2012.79)

Knoop K, Schwenk N, Dolp P, Willhauck MJ, Zischek C, Zach C, Hacker M, Göke B, Wagner E, Nelson PJ et al. 2013 Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma. Human Gene Therapy 24 306–316. (doi:10.1089/hum.2012.104)

Vetter A, Virdi KS, Espenlaub S, Rödl W, Wagner E, Holm PS, Scheu C, Kreppel F, Spitzweg C & Ogris M 2013 Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor. Molecular Pharmaceutics 10 606–618. (doi:10.1021/mp300366f)

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B et al. 2013 EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene. Molecular Therapy. Nucleic Acids 2 e131. (doi:10.1038/mtna.2013.58)

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B et al. 2013 EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene. Molecular Therapy. Nucleic Acids 2 e131. (doi:10.1038/mtna.2013.58)

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B et al. 2013 EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene. Molecular Therapy. Nucleic Acids 2 e131. (doi:10.1038/mtna.2013.58)

Kollecker I, Wasielewski von R, Langner C, Müller JA, Spitzweg C, Kreipe H & Brabant G 2012 Subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues. Thyroid : Official Journal of the American Thyroid Association 22 529–535. (doi:10.1089/thy.2011.0311)

Schäfer A, Pahnke A, Schaffert D, van Weerden WM, de Ridder CMA, Rödl W, Vetter A, Spitzweg C, Kraaij R, Wagner E et al. 2011 Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. Human Gene Therapy 22 1463–1473. (doi:10.1089/hum.2010.231)

Klutz K, Willhauck MJ, Wunderlich N, Zach C, Anton M, Senekowitsch-Schmidtke R, Göke B & Spitzweg C 2011 Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery. Human Gene Therapy 22 1403–1412. (doi:10.1089/hum.2010.158)

Knoop K, Kolokythas M, Klutz K, Willhauck MJ, Wunderlich N, Draganovici D, Zach C, Gildehaus FJ, Böning G, Göke B et al. 2011 Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Molecular Therapy : the Journal of the American Society of Gene Therapy 19 1704–1713. (doi:10.1038/mt.2011.93)

Willhauck MJ, Schott M, Kreissl MC, Fassnacht M & Spitzweg C 2011 [New therapeutic options for advanced thyroid cancer]. Deutsche Medizinische Wochenschrift (1946) 136 1165–1168. (doi:10.1055/s-0031-1280531)

Klutz K, Schaffert D, Willhauck MJ, Grünwald GK, Haase R, Wunderlich N, Zach C, Gildehaus FJ, Senekowitsch-Schmidtke R, Göke B et al. 2011 Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Molecular Therapy : the Journal of the American Society of Gene Therapy 19 676–685. (doi:10.1038/mt.2010.296)

Willhauck MJ, O Kane DJ, Wunderlich N, Göke B & Spitzweg C 2011 Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of ¹³¹I by carbamazepine in breast cancer cells. Breast Cancer Research and Treatment 125 377–386. (doi:10.1007/s10549-010-0835-x)

Spitzweg C & Morris JC 2010 Genetics and phenomics of hypothyroidism and goiter due to NIS mutations. Molecular and Cellular Endocrinology 322 56–63. (doi:10.1016/j.mce.2010.02.007)

Spitzweg C & Reincke M 2010 [Thyroid diseases and hypertension]. Der Internist 51 603–4–606–8–610. (doi:10.1007/s00108-009-2499-3)

Ditsch N, Liebhardt S, Koch Von F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J & Toth B 2010 Thyroid function in breast cancer patients. Anticancer Research 30 1713–1717.

Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, Vile R & Harrington K 2010 The biology of the sodium iodide symporter and its potential for targeted gene delivery. Current Cancer Drug Targets 10 242–267.

Klutz K, Russ V, Willhauck MJ, Wunderlich N, Zach C, Gildehaus FJ, Göke B, Wagner E, Ogris M & Spitzweg C 2009 Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 15 6079–6086. (doi:10.1158/1078-0432.CCR-09-0851)

Spitzweg C 2009 Gene therapy in thyroid cancer. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme 41 500–509. (doi:10.1055/s-0029-1220744)

Popp H, Spiekermann K, Wollenberg A, Spitzweg C & Loehrs B 2009 [Hematologic neoplasias and solid tumors in pregnancy. Part 2: Specific treatment]. Deutsche Medizinische Wochenschrift (1946) 134 361–364. (doi:10.1055/s-0028-1124006)

Schollen A, Spitzweg C & Vogeser M 2009 Case report: over-substitution of thyroxine due to interference in serum thyroid-stimulating hormone measurement. Clinical Chemistry and Laboratory Medicine : CCLM / FESCC 47 498–499. (doi:10.1515/CCLM.2009.101)

Spitzweg C, Hay ID & Morris JC 2009 Prospects for Gene Therapy for Endocrine Malignancies. Clinical Endocrine Oncology.

Spitzweg C, Morris JC: The sodium iodide symporter (NIS): NIS-mediated radioiodide therapy. In: Preedy VR, Burrow GN, Watson RR, Hrsg. Comprehensive Handbook on Iodine: Nutritional, Endocrine and Pathological Aspects, 1. Auflage, Elsevier 2008.

Willhauck MJ & Spitzweg C 2008 [Graves' disease]. MMW Fortschritte Der Medizin 150 31–35.

Willhauck MJ, Samani B-RS, Wolf I, Senekowitsch-Schmidtke R, Stark H-J, Meyer GJ, Knapp WH, Göke B, Morris JC & Spitzweg C 2008 The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 35 1272–1281. (doi:10.1007/s00259-008-0775-4)

Willhauck MJ, Sharif-Samani B, Senekowitsch-Schmidtke R, Wunderlich N, Göke B, Morris JC & Spitzweg C 2008 Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. Breast Cancer Research and Treatment 109 263–272. (doi:10.1007/s10549-007-9646-0)

Willhauck MJ, Sharif-Samani B, Senekowitsch-Schmidtke R, Wunderlich N, Göke B, Morris JC & Spitzweg C 2008 Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. Breast Cancer Research and Treatment 109 263–272. (doi:10.1007/s10549-007-9646-0)

Willhauck MJ, Sharif-Samani B, Senekowitsch-Schmidtke R, Wunderlich N, Göke B, Morris JC & Spitzweg C 2008 Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. Breast Cancer Research and Treatment 109 263–272. (doi:10.1007/s10549-007-9646-0)

Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L, Geissler M, Senekowitsch-Schmidtke R, Göke B, Morris JC et al. 2008 Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Therapy 15 214–223. (doi:10.1038/sj.gt.3303057)

Spitzweg C, Baker CH, Bergert ER, O'Connor MK & Morris JC 2007 Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Human Gene Therapy 18 916–924. (doi:10.1089/hum.2007.081)

Berger F, Unterholzner S, Diebold J, Knesewitsch P, Hahn K & Spitzweg C 2006 Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma. Biochemical and Biophysical Research Communications 349 1258–1263. (doi:10.1016/j.bbrc.2006.08.170)

Leech C, Lohse P, Stanojevic V, Lechner A, Göke B & Spitzweg C 2006 Identification of a novel inactivating R465Q mutation of the calcium-sensing receptor. Biochemical and Biophysical Research Communications 342 996–1002.

Unterholzner S, Willhauck MJ, Cengic N, Schütz M, Göke B, Morris JC & Spitzweg C 2006 Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells. The Journal of Clinical Endocrinology and Metabolism 91 69–78. (doi:10.1210/jc.2005-0779)

Cengic N, Baker CH, Schütz M, Göke B, Morris JC & Spitzweg C 2005 A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. The Journal of Clinical Endocrinology and Metabolism 90 4457–4464. (doi:10.1210/jc.2004-2140)

Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER, Vile R, Göke B, Morris JC & Spitzweg C 2005 Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Therapy 12 272–280. (doi:10.1038/sj.gt.3302410)

Miyagawa M, Beyer M, Wagner B, Anton M, Spitzweg C, Gansbacher B, Schwaiger M & Bengel FM 2005 Cardiac reporter gene imaging using the human sodium/iodide symporter gene. Cardiovascular Research 65 195–202. (doi:10.1016/j.cardiores.2004.10.001)

Spitzweg C & Morris JC 2004 Gene therapy for thyroid cancer: current status and future prospects. Thyroid : Official Journal of the American Thyroid Association 14 424–434. (doi:10.1089/105072504323150732)

Spitzweg C 2004 [The practical relevance of the sodium iodide symporter]. Zeitschrift Für Ärztliche Fortbildung Und Qualitätssicherung 98 Suppl 5 25–32.

Scholz IV, Cengic N, Göke B, Morris JC & Spitzweg C 2004 Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. The Journal of Clinical Endocrinology and Metabolism 89 1108–1116.

Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM & Morris JC 2003 Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Research 63 7840–7844.

Spitzweg C, Scholz IV, Bergert ER, Tindall DJ, Young CYF, Göke B & Morris JC 2003 Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology 144 3423–3432.

Spitzweg C 2003 [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance]. Der Internist 44 396–402–404–8–410–1.

Spitzweg C & Morris JC 2002 The sodium iodide symporter: its pathophysiological and therapeutic implications. Clinical Endocrinology 57 559–574.

Spitzweg C & Morris JC 2002 Sodium iodide symporter (NIS) and thyroid. Hormones (Athens, Greece) 1 22–34.

Pinke LA, Dean DS, Bergert ER, Spitzweg C, Dutton CM & Morris JC 2001 Cloning of the mouse sodium iodide symporter. Thyroid : Official Journal of the American Thyroid Association 11 935–939. (doi:10.1089/105072501753210993)

Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY & Morris JC 2001 In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 8 1524–1531. (doi:10.1038/sj.gt.3301558)

Spitzweg C, Harrington KJ, Pinke LA, Vile RG & Morris JC 2001 Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. The Journal of Clinical Endocrinology and Metabolism 86 3327–3335.

Spitzweg C, Dutton CM, Castro MR, Bergert ER, Goellner JR, Heufelder AE & Morris JC 2001 Expression of the sodium iodide symporter in human kidney. Kidney International 59 1013–1023. (doi:10.1046/j.1523-1755.2001.0590031013.x)

Spitzweg C & Morris JC 2001 Approaches to gene therapy with sodium/iodide symporter. Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association 109 56–59. (doi:10.1055/s-2001-11020)

Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY & Morris JC 2000 Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Research 60 6526–6530.

Spitzweg C & Morris JC 2000 The immune response to the iodide transporter. Endocrinology and Metabolism Clinics of North America 29 389–98–viii.

Spitzweg C, Heufelder AE & Morris JC 2000 Thyroid iodine transport. Thyroid : Official Journal of the American Thyroid Association 10 321–330.

Mühlberg T, Joba W, Spitzweg C, Schworm HD, Heberling HJ & Heufelder AE 2000 Interleukin-1 receptor antagonist ribonucleic acid and protein expression by cultured Graves' and normal orbital fibroblasts is differentially modulated by dexamethasone and irradiation. The Journal of Clinical Endocrinology and Metabolism 85 734–742.

Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC & Heufelder AE 1999 Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. The Journal of Clinical Endocrinology and Metabolism 84 4178–4184.

Spitzweg C & Heufelder AE 1999 [Sodium-iodine symporter of the thyroid gland. Discovery, characterization, clinical relevance and prospects]. Deutsche Medizinische Wochenschrift (1946) 124 1077–1084. (doi:10.1055/s-2007-1024485)

Spitzweg C, Joba W, Morris JC & Heufelder AE 1999 Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid : Official Journal of the American Thyroid Association 9 821–830.

Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY & Morris JC 1999 Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Research 59 2136–2141.

Joba W, Spitzweg C, Schriever K & Heufelder AE 1999 Analysis of human sodium/iodide symporter, thyroid transcription factor-1, and paired-box-protein-8 gene expression in benign thyroid diseases. Thyroid : Official Journal of the American Thyroid Association 9 455–466.

Spitzweg C, Joba W & Heufelder AE 1999 Expression of thyroid-related genes in human thymus. Thyroid : Official Journal of the American Thyroid Association 9 133–141.

Heufelder AE & Spitzweg C 1999 Immunology of Graves' ophthalmopathy. Developments in Ophthalmology 30 24–38.

Spitzweg C, Rossmüller B & Heufelder AE 1998 Radioiodine therapy and Graves' ophthalmopathy. Thyroid : Official Journal of the American Thyroid Association 8 1193.

Heufelder AE & Spitzweg C 1998 [Pathogenesis of immunogenic hyperthyroidism and endocrine orbitopathy]. Der Internist 39 599–606.

Mühlberg T, Kirchberger M, Spitzweg C, Herrmann F, Heberling HJ & Heufelder AE 1998 Lack of association of Graves' disease with the A2 allele of the interleukin-1 receptor antagonist gene in a white European population. European Journal of Endocrinology / European Federation of Endocrine Societies 138 686–690.

Spitzweg C, Joba W, Eisenmenger W & Heufelder AE 1998 Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. The Journal of Clinical Endocrinology and Metabolism 83 1746–1751.

Spitzweg C & Heufelder AE 1998 The sodium iodide symporter: its emerging relevance to clinical thyroidology. European Journal of Endocrinology / European Federation of Endocrine Societies 138 374–375.

Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C & Heufelder AE 1998 Thyrotropin receptor expression in Graves“ orbital adipose/connective tissues: potential autoantigen in Graves” ophthalmopathy. The Journal of Clinical Endocrinology and Metabolism 83 998–1002.

Dutton CM, Joba W, Spitzweg C, Heufelder AE & Bahn RS 1997 Thyrotropin receptor expression in adrenal, kidney, and thymus. Thyroid : Official Journal of the American Thyroid Association 7 879–884.

Spitzweg C & Heufelder AE 1997 Pathogenesis of Graves' ophthalmopathy. International Archives of Allergy and Immunology 114 101–102.

Hoermann R, Spitzweg C, Poertl S, Mann K, Heufelder AE & Schumm-Draeger PM 1997 Regulation of intercellular adhesion molecule-1 expression in human thyroid cells in vitro and human thyroid tissue transplanted to the nude mouse in vivo: role of Graves' immunoglobulins and human thyrotropin receptor. The Journal of Clinical Endocrinology and Metabolism 82 2048–2055.

Spitzweg C & Heufelder AE 1997 Update on the thyroid sodium iodide symporter: a novel thyroid antigen emerging on the horizon. European Journal of Endocrinology / European Federation of Endocrine Societies 137 22–23.

Spitzweg C, Joba W, Hunt N & Heufelder AE 1997 Analysis of human thyrotropin receptor gene expression and immunoreactivity in human orbital tissue. European Journal of Endocrinology / European Federation of Endocrine Societies 136 599–607.

Spitzweg C, Hofbauer LC & Heufelder AE 1997 Dermatitis herpetiformis cured by hormone replacement for panhypopituitarism. Endocrine Journal 44 437–440.

Spitzweg C & Heufelder AE 1997 More clues from fat mice: leptin acts as an opponent of the hypothalamic neuropeptide Y system. European Journal of Endocrinology / European Federation of Endocrine Societies 136 590–591.

Hofbauer LC, Spitzweg C, Schmauss S & Heufelder AE 1997 Graves disease associated with autoimmune thrombocytopenic purpura. Archives of Internal Medicine 157 1033–1036.

Hofbauer LC, Spitzweg C, Magerstädt RA & Heufelder AE 1997 Selenium-induced thyroid dysfunction. Postgraduate Medical Journal 73 103–104.

Stadlmayr W, Spitzweg C, Bichlmair AM & Heufelder AE 1997 TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema. Thyroid : Official Journal of the American Thyroid Association 7 3–12.

Spitzweg C, Hofbauer LC, Landgraf R & Heufelder AE 1996 [The molecular pathogenesis of obesity. The physiological and pathophysiological role of leptin]. Deutsche Medizinische Wochenschrift (1946) 121 1134–1138. (doi:10.1055/s-2008-1043117)

Hofbauer LC, Spitzweg C & Heufelder AE 1996 Graves' disease associated with the primary antiphospholipid syndrome. The Journal of Rheumatology 23 1435–1437.

Hofbauer LC, Spitzweg C, Tammen AR & Heufelder AE 1996 [Infectious thyroiditis as initial manifestation of embolizing endocarditis of the aortic valve]. Deutsche Medizinische Wochenschrift (1946) 121 369–374. (doi:10.1055/s-2008-1043014)